- Leflunomide: A promising drug with good antitumor potential
Chunying Zhang et al, 2018, Biochemical and Biophysical Research Communications CrossRef - Recent advances of human dihydroorotate dehydrogenase inhibitors for cancer therapy: Current development and future perspectives
Lele Zhang et al, 2022, European Journal of Medicinal Chemistry CrossRef - Cell-Based Double-Screening Method to Identify a Reliable Candidate for Osteogenesis-Targeting Compounds
Sho Fukuyasu et al, 2022, Biomedicines CrossRef - Leflunomide Synergizes with Gemcitabine in Growth Inhibition of PC Cells and Impairs c-Myc Signaling through PIM Kinase Targeting
Ralf Buettner et al, 2019, Molecular Therapy - Oncolytics CrossRef - AhR and Cancer: From Gene Profiling to Targeted Therapy
Anaïs Paris et al, 2021, International Journal of Molecular Sciences CrossRef - Drug Repurposing Opportunities in Cancer
Popat Kumbhar et al, 2023, Drug Repurposing for Emerging Infectious Diseases and Cancer CrossRef - Epigenetic landscape of drug responses revealed through large-scale ChIP-seq data analyses
Zhaonan Zou et al, 2022, BMC Bioinformatics CrossRef - A Patent Review of Human Dihydroorotate Dehydrogenase (hDHODH) Inhibitors as Anticancer Agents and their Other Therapeutic Applications (1999-2022)
Pinky Gehlot et al, 2024, Recent Patents on Anti-Cancer Drug Discovery CrossRef - Synthesis, characterization, electrochemical and DNA binding studies of regio-isomeric sulfonyl esters of substituted isoxazoles
Mehwash Zia et al, 2020, Journal of Molecular Structure CrossRef - The Mitochondria-Independent Cytotoxic Effect of Leflunomide on RPMI-8226 Multiple Myeloma Cell Line
Grzegorz Adamczuk et al, 2021, Molecules CrossRef - Revisiting the role of dihydroorotate dehydrogenase as a therapeutic target for cancer
Joseph T. Madak et al, 2019, Pharmacology & Therapeutics CrossRef - Drug repurposing: An emerging strategy in alleviating skin cancer
Popat Kumbhar et al, 2022, European Journal of Pharmacology CrossRef